Research
BPC-157 Research Overview
Proposed mechanisms, preclinical research areas, and an honest evidence-quality assessment.
BPC-157 ('Body Protection Compound-157') is a synthetic 15-amino-acid peptide (a pentadecapeptide) derived from a sequence found in human gastric juice. It is one of the most frequently studied peptides in preclinical regenerative research.
Evidence status: As of 2026 there are NO completed, controlled human efficacy trials of BPC-157. The evidence base is almost entirely preclinical (cell and animal studies), plus one small 2024 pilot in 12 patients. Animal results often do not translate to humans — treat every claim below as a hypothesis, not a proven effect.
Proposed mechanisms (from preclinical work)
- Angiogenesis: upregulation of VEGFR2 signaling, promoting new blood-vessel formation at injury sites in animal models.
- Nitric-oxide pathway: modulation of the NO system, implicated in vascular and cytoprotective effects.
- Growth-factor cascade: increased Egr-1 expression, driving FGF/PDGF-type signaling and fibroblast activity.
- Tissue models: accelerated tendon, ligament, muscle, bone and gastrointestinal healing in rodents.
Preclinical research areas
- Tendon-to-bone and ligament healing (rat models).
- Gastrointestinal protection: ulcer and inflammatory-bowel models.
- General cytoprotection of tissues after injury.
Regulatory & anti-doping status
- Not approved for human use by any global regulatory authority.
- Prohibited by WADA at all times under category S0 (Unapproved Substances) since 2022; not eligible for a Therapeutic Use Exemption.
- U.S. regulators have flagged BPC-157 in consumer products as an unapproved drug.
For laboratory research and education only. Not medical advice and not for human use.
For research and educational purposes only. Not medical advice; these compounds are not approved for human use.